Immunologic changes during treatment with romidepsin, azacitidine, and lenalidomide in relapse/refractory T-cell lymphoma. // Blood Neoplasia. – URL: https://www.sciencedirect.com/science/article/pii/S2950328026000981?dgcid=rss_sd_all
Immunologic changes during treatment with romidepsin, azacitidine, and lenalidomide in relapse/refractory T-cell lymphoma. Blood Neoplasia. https://www.sciencedirect.com/science/article/pii/S2950328026000981?dgcid=rss_sd_all
“Immunologic changes during treatment with romidepsin, azacitidine, and lenalidomide in relapse/refractory T-cell lymphoma.” Blood Neoplasia.
@article{article38365,
title = {Immunologic changes during treatment with romidepsin, azacitidine, and lenalidomide in relapse/refractory T-cell lymphoma},
journal = {Blood Neoplasia},
url = {https://www.sciencedirect.com/science/article/pii/S2950328026000981?dgcid=rss_sd_all}
}